HIGHER BIOLOGICALLY EFFECTIVE DOSE OF RADIOTHERAPY IS ASSOCIATED WITH IMPROVED OUTCOMES FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CARCINOMA TREATED WITH CHEMORADIATION: AN ANALYSIS OF THE RADIATION THERAPY ONCOLOGY GROUP

• Type of Material: Article
• Authors: Mitchell Machtay, Case Western Reserve University; Kyounghwa Bae, Radiation Therapy Oncology Group (RTOG) Department of Statistics; Benjamin Movsas, Henry Ford Hospital; Rebecca Paulus, Radiation Therapy Oncology Group (RTOG) Department of Statistics; Elizabeth M. Gore, Medical College of Wisconsin; Ritsuko Komaki, MD Anderson Cancer Center; Kathy Albain, Loyola University Chicago Stritch School of Medicine; William T. Sause, LDS Hospital; Walter J Curran, Emory University
• Language: English
• Date: 2012-01-01
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2012 Elsevier Inc. Printed in the USA. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.ijrobp.2010.09.004
• Title of Journal or Parent Work: International Journal of Radiation Oncology - Biology - Physics
• ISSN: 0360-3016
• Volume: 82
• Issue: 1
• Start Page: 425
• End Page: 434
• Grant/Funding Information: This paper's contents are the sole responsibility of the authors and do not necessarily represent the official views of the NCI; This paper is supported by RTOG U10 CA21661 and CCOP U10 CA37422 grants from the NCI.
• Keywords: Radiation oncology; FOLLOW-UP; Radiology, Nuclear Medicine & Medical Imaging; THORACIC RADIOTHERAPY; Life Sciences & Biomedicine; INDUCTION CHEMOTHERAPY; Local-regional failure; CONSOLIDATION DOCETAXEL; PHASE-III TRIAL; Chemoradiotherapy; Survival with respect to radiotherapy dose intensity; HYPERFRACTIONATED RADIATION; CANCER; Advanced non-small-cell lung carcinoma; CONCURRENT CHEMORADIATION; Oncology; COMPETING RISK; LEUKEMIA GROUP-B; Science & Technology
• Research Categories: Health Sciences, Oncology

Abstract

Purpose: Patients treated with chemoradiotherapy for locally advanced non-small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials: This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray's proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. Results: A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis (p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. Conclusions: Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy.